Licensing In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer to fund Phase III ProMune trials for lung cancer under licensing pact valued at up to $505 mil., plus royalties. Medicis gains Botox competitor in $2.8 bil. Inamed purchase. Baxter gets U.S. rights to Cangene WinRho SDF for bleeding disorder. More licensing deals in brief
|
Medicis gets Botox competitor in Inamed purchase: Medicis' $2.8 bil. acquisition of Inamed will add the botulinum toxin type A product Reloxin to its pipeline as well as aesthetic devices including wrinkle treatments, breast implants and bariatric surgery systems. Currently in Phase III trials, Reloxin is expected to compete with Allergan's Botox (botulinum toxin type A). Inamed has exclusive rights to market Reloxin in the U.S. and Canada under an agreement with Paris-based Ipsen, and a preliminary agreement for international rights, Inamed explained March 21.... Baxter gains rights to Cangene WinRho SDF: Exclusive U.S. marketing and distribution rights to bleeding disorder therapy WinRho SDF (Rho(D) immune globulin) are acquired by Baxter under a March 28 agreement. Cangene will continue to manufacture WinRho for Baxter, which markets the product in the UK under an existing agreement. Cangene announced approval of a liquid formulation April 11; set for a U.S. launch by Baxter later this year, the liquid eases administration by eliminating the need for reconstitution of the earlier freeze-dried version. WinRho SDF has been marketed for immune thrombocytopenic purpura treatment since 1995.... Pfizer/Coley to produce ProMune: Pfizer will fund future development of Coley's ProMune (CPG 7909), including planned Phase III trials for non-small cell lung cancer, under a joint development and commercialization deal announced March 24. Privately held Coley could receive up to $505 mil., including $50 mil. up-front and up to $455 mil. in additional milestone payments under the agreement, plus royalties. Other tumor types will be explored under the deal. The toll-like receptor-9 agonist has shown "promising" initial anti-cancer activity in Phase II studies, Pfizer says.... Novartis adds Phase II COPD drug: Novartis will develop AD 237 for treatment of chronic obstructive pulmonary disease under a global development and commercialization agreement with current developers Arakis and Vectura, the firms announce April 13. Currently in Phase II studies, Novartis will evaluate the once-daily, long-acting antimuscarinic agent as both monotherapy and for use in combination with its once-daily beta2 agonist QAB149, also in Phase II. Initial payments and milestones of up to $375 mil. would be split 50-50 by Arakis and Vectura. The firms expect the COPD market, currently valued at $4 bil., to grow to $10 bil. by 2010.... |